Deliverables
IC memo, valuation model, and diligence report · drafted from your templates on the data room
RON's read on your deliverables
Drafted using your uploaded templates · ready for review
Three IC deliverables in flight — the valuation model is the gating item.
  • IC Memo · 70%. Risks & mitigants section in progress; concentration is the headline.
  • Valuation Model · blocked. Waiting on the 2024 audited financials before it can finalize.
  • Diligence Report · 71%. Tech and commercial workstreams still open.
DOCX
IC Memo · Lumina Health Systems
Auto-drafted by RON using your IC Memo Template.docx
Due in 10d
Risks & mitigants in progress · concentration is the headline risk
100%
XLSX
Valuation Model · Lumina
Auto-drafted by RON using your LBO Model Template.xlsx
Due in 8d
Blocked · awaiting 2024 audited financials
75%
DOCX
Diligence Report · Lumina
Auto-drafted by RON using your QoE / DD Report Template.docx
Due in 12d
5 of 7 workstreams complete · tech & commercial remaining
100%
Monthly Board Update — April 2026
Editing slide 5 of 8 · using Q1 Board Deck.pptx · auto-saved 12s ago
1
Lumina Health Systems
Board Update
April 2026
Cover
2
Executive Summary
▪ Strong NRR
▪ Pipeline soft
▪ Lumina risk
Exec Summary
3
ARR & Growth
$8.4M ARR
+22% YoY
ARR & Growth
4
Retention
NRR 117%
GRR 94%
NRR / GRR
5
Pipeline
2.8× coverage
Win rate 38%
Pipeline
6
Risks
Lumina churn
signal
Risks & mitigation
7
Hiring
Needs your
input
Hiring update
8
Q&A Prep
Needs your
input
Q&A prep
Slide 5 of 8 · Pipeline
Board Update · April 2026 · p.5
Pipeline & Sales Velocity
Coverage softened, win rate down 3 points
Pipeline Coverage
2.8×
▼ −0.4× vs Q1
Win Rate
38%
▼ −3 pts
New ARR · QTD
$420K
▲ +12% MoM
Avg ACV
$72K
▲ +8% YoY
What's behind the numbers
  • Pipeline coverage at 2.8× is below our 3.0× minimum. Late-stage slippage drove the drop, not top-of-funnel weakness — top-of-funnel volume is healthy.
  • Win rate fell 3 points to 38%. 7 of 11 closed-lost this quarter went to "no decision" — champions couldn't mobilize budget. Channel-sourced deals continue to win at 47%.
  • ACV is up 8% — better mid-market discovery + favorable mix shift. Healthy underlying motion despite headline win-rate softness.
Action being taken: Adding stage-4 economic-buyer gate to opportunity process this quarter; Lumina & Brightpoint deals (combined $204K) being personally worked by leadership before quarter-end.